Documented Patient Outcomes

Ibogaine Treatment Case Studies

Real patient journeys documenting outcomes from ibogaine TA (Total Alkaloid) treatment using the complete alkaloid spectrum of Tabernanthe iboga.

8
Case Studies
6
Conditions Treated
100%
TA Protocol
12+
Active Alkaloids

Why TA Outcomes Differ from Standard Ibogaine HCL

The critical pharmacological distinction most patients never learn about until it is too late

TA

Ibogaine TA (Total Alkaloid)

Used by a small number of specialized clinics worldwide

  • +Extracted from Tabernanthe iboga root bark -- the authentic African source plant
  • +Contains all 12+ alkaloids including ibogaine, ibogamine, tabernanthine, voacangine, ibogaline, and others
  • +Alkaloids work synergistically -- broader receptor coverage, smoother onset, deeper therapeutic experience
  • +More complete opioid receptor modulation (mu, kappa, delta subtypes simultaneously)
  • +Enhanced GDNF production, serotonergic and dopaminergic modulation from full-spectrum alkaloid profile
  • +Rare formulation -- only a handful of clinics worldwide administer genuine TA from Tabernanthe iboga
HCL

Ibogaine HCL (Hydrochloride)

Used at most other clinics worldwide

  • -Semi-synthesized from Voacanga africana-- a completely different African plant, not true iboga
  • -Contains only 1 isolated alkaloid(ibogaine hydrochloride) -- the other 11+ alkaloids are absent
  • -No synergistic alkaloid interaction -- narrower pharmacological action
  • -Limited receptor coverage compared to full-spectrum TA
  • -Less sustained GDNF upregulation and reduced serotonergic modulation
  • -More widely available but pharmacologically inferior to the complete plant extract

Why does this matter?

The iboga plant evolved its alkaloid profile over millions of years. Each alkaloid contributes to the therapeutic effect -- ibogamine modulates serotonin receptors, tabernanthine acts on calcium channels, voacangine provides additional opioid receptor activity. Isolating a single alkaloid from a substitute plant is like extracting one instrument from an orchestra and expecting the same music.Every case study on this page reflects outcomes achieved with genuine TA from Tabernanthe iboga -- not HCL fromVoacanga africana.

Learn More About Ibogaine TA

Patient Case Studies

Each case below represents a documented patient journey through ibogaine TA treatment. Names and identifying details have been changed to protect patient privacy.

CASE 01Opioid Addiction

Fentanyl Addiction Recovery

From daily fentanyl use and five failed rehab attempts to 18 months of sustained freedom

“I did five detoxes and two rehabs. Every single time I went back to fentanyl within weeks. Ibogaine didn't just stop the withdrawal -- it showed me why I was using in the first place. I woke up the next day and the obsession was gone. Not managed. Gone.”

Patient Profile

Age Range
Late 20s
Condition
Fentanyl dependence (pressed pills and powder)
Duration
3+ years of daily use

Previous Treatment Attempts

  • ×Five medically supervised detox programs
  • ×Two 90-day inpatient rehabilitation stays
  • ×Suboxone maintenance (8 months, relapsed)
  • ×Methadone clinic (14 months, could not taper)
  • ×Outpatient counseling and 12-step programs

Ibogaine TA Treatment Experience

After comprehensive medical screening including cardiac evaluation and blood panels, the patient received ibogaine TA (Total Alkaloid) at a specialized clinic in Cozumel, Mexico. The flood dose was administered under 24/7 cardiac monitoring with continuous ECG telemetry. Within hours of the ibogaine experience beginning, acute withdrawal symptoms that had started during the pre-treatment stabilization period began to resolve. By the following morning, the patient reported zero withdrawal symptoms -- a stark contrast to the 10-14 days of brutal withdrawal experienced during previous detox attempts. The introspective phase of the experience revealed deep-rooted trauma from adolescence that the patient identified as the origin of self-medicating behavior.

Outcome

Complete elimination of acute withdrawal within 12 hours. No post-acute withdrawal syndrome (PAWS). Cravings reduced by approximately 90% in the first three months, gradually diminishing further. The patient credits the TA formulation's multi-alkaloid profile for the depth of both the physical reset and psychological processing.

Current Status

18 months opioid-free. Employed full-time. Rebuilt relationship with family. Participates in integration therapy monthly. No relapse episodes. Describes the difference between ibogaine TA and previous treatments as 'night and day -- everything else was a bandage, this was surgery on the root cause.'

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

CASE 02Prescription Opioids

Oxycodone to Freedom

A prescription painkiller dependency that escalated over five years, resolved in a single session

“My doctor kept increasing the dose until I was taking OxyContin around the clock. One ibogaine session did what five years of trying to quit on my own could never accomplish. The pills had taken everything from me -- my energy, my relationships, my identity. I got it all back in one night.”

Patient Profile

Age Range
Early 40s
Condition
Prescription opioid dependence (Vicodin escalating to OxyContin)
Duration
5 years, beginning after back surgery

Previous Treatment Attempts

  • ×Pain management clinic (dose escalation, not reduction)
  • ×Attempted cold-turkey withdrawal twice (failed both times)
  • ×Suboxone taper program (6 months, relapsed during final taper)
  • ×Cognitive behavioral therapy (helpful but insufficient alone)
  • ×Acupuncture and holistic approaches (minimal effect on dependence)

Ibogaine TA Treatment Experience

The patient arrived at a specialized ibogaine clinic taking 120mg of OxyContin daily -- a dose that had escalated steadily from an initial 10mg Vicodin prescription post-surgery. Medical screening confirmed healthy cardiac function and liver panels. Following a supervised reduction schedule over 48 hours, the ibogaine TA flood dose was administered. The patient described the experience as 'the most intense 18 hours of my life' -- cycling through vivid autobiographical memories that contextualized how the pain medication had evolved from medical necessity into psychological dependence. The multi-alkaloid TA formulation provided sustained receptor modulation throughout the experience.

Outcome

Withdrawal symptoms eliminated within the first 24 hours. The patient reported that chronic back pain -- the original reason for the prescription -- actually decreased in intensity after treatment, likely due to ibogaine's anti-inflammatory and neuroplastic properties. Opioid cravings dropped to near-zero and remained suppressed for months through the action of noribogaine, ibogaine's long-acting metabolite.

Current Status

14 months opioid-free. Manages residual back pain through physical therapy and non-opioid interventions. Has returned to recreational activities (cycling, hiking) abandoned during the years of escalating opioid use. Reports improved sleep quality and emotional regulation.

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

CASE 03PTSD + Addiction

Veteran PTSD & Opioid Dual Diagnosis

A combat veteran trapped between untreated PTSD and opioid self-medication finds resolution for both

“The VA gave me pills for the PTSD and a different program for the addiction, like they were separate problems. They weren't. I was using because of the war. Ibogaine let me process the combat trauma and broke the addiction in the same session. Nothing else even came close.”

Patient Profile

Age Range
Mid 30s
Condition
Combat-related PTSD with co-occurring opioid dependence (heroin, later fentanyl)
Duration
PTSD: 8 years post-deployment. Opioid use: 6 years, beginning as self-medication

Previous Treatment Attempts

  • ×VA psychiatric care (SSRIs, prazosin, trazodone -- partial relief)
  • ×Prolonged Exposure Therapy at VA (3 rounds, could not complete due to re-traumatization)
  • ×EMDR (some benefit for specific memories, did not address addiction)
  • ×VA substance abuse program (12 weeks inpatient, relapsed within 30 days)
  • ×Medication-assisted treatment with buprenorphine (stabilized use but did not address PTSD)

Ibogaine TA Treatment Experience

This case required careful coordination. The patient was tapered off buprenorphine over two weeks under medical supervision before the ibogaine TA session. The clinical team, experienced with veteran populations, structured the set and setting to support trauma processing. During the ibogaine experience, the patient reported processing combat memories with a clarity and emotional distance that years of talk therapy had not achieved. The TA formulation's full alkaloid spectrum -- particularly the presence of ibogamine and tabernanthine alongside ibogaine -- appeared to facilitate a deeper, more sustained introspective state. The patient described 'watching the memories like a movie rather than reliving them.'

Outcome

PTSD symptoms reduced dramatically: nightmares decreased from nightly to approximately once per month. Hypervigilance substantially diminished. The opioid dependence was simultaneously resolved -- acute withdrawal eliminated within hours, cravings reduced by approximately 85%. The patient reported this was the first time any treatment had addressed both conditions simultaneously rather than forcing a choice between treating addiction OR trauma.

Current Status

16 months opioid-free with sustained PTSD symptom reduction. Completed a vocational training program. Reestablished relationship with spouse and children. Participates in a veteran peer support group. No longer takes psychiatric medications. Reports that the ibogaine experience provided more therapeutic progress than eight years of conventional treatment combined.

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

CASE 04Methadone Dependence

Methadone Liberation

Told they would be on methadone for life -- after 8 years, ibogaine TA treatment proved otherwise

“Eight years. Every single morning at the methadone clinic at 6 AM. My doctor told me I would be on it for life. Two different tapers nearly killed me. Ibogaine got me free in a week. I remember walking out of the clinic and thinking, 'I'm actually done. After eight years, I'm done.'”

Patient Profile

Age Range
Late 40s
Condition
Methadone maintenance dependence (originally prescribed for heroin addiction)
Duration
8 years on daily methadone (stabilized at 80mg/day), original heroin use for 6 years prior

Previous Treatment Attempts

  • ×Methadone maintenance program (8 years, physician advised against tapering)
  • ×Two attempted methadone tapers (both abandoned due to protracted withdrawal lasting months)
  • ×Counseling throughout methadone maintenance (helpful for coping, did not enable cessation)
  • ×Attempted switch to buprenorphine (precipitated withdrawal, abandoned)
  • ×Cold-turkey methadone cessation attempt (hospitalized after 5 days of severe withdrawal)

Ibogaine TA Treatment Experience

Methadone cases are among the most challenging for ibogaine treatment due to methadone's extremely long half-life and deep receptor binding. The clinical team implemented a specialized protocol: a supervised methadone taper over 3 weeks (from 80mg to 30mg), followed by a short morphine bridge, then the ibogaine TA flood dose. The extended TA protocol -- which included a primary flood dose followed by two booster doses over three days -- was specifically designed for the depth of methadone receptor occupation. The patient described the experience as 'being taken apart and rebuilt,' processing eight years of emotional numbness that the methadone had created.

Outcome

Methadone withdrawal -- historically the most protracted and agonizing opioid withdrawal, lasting 30-60 days -- was reduced to mild discomfort lasting approximately 72 hours. The patient completed the full treatment protocol and left the clinic methadone-free for the first time in eight years. The TA formulation's complete alkaloid profile was critical here: the synergistic action of multiple iboga alkaloids provided the sustained receptor modulation necessary to overcome methadone's deep pharmacological footprint.

Current Status

12 months methadone-free and opioid-free. No longer visits the methadone clinic daily -- a routine that had defined their life for nearly a decade. Reports restored emotional range ('I can actually feel things again -- joy, sadness, all of it'), improved cognitive clarity, and significant weight loss attributed to restored metabolism. Currently mentoring others considering ibogaine treatment for methadone dependence.

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

CASE 05Kratom / 7-OH

Kratom & 7-OH Addiction

A 'natural alternative' that became a devastating dependency -- resolved through ibogaine TA receptor reset

“Everyone told me kratom was natural and safe. By the time I was on 7-OH extracts, I was spending $300 a week and couldn't go four hours without dosing. The withdrawal was as bad as anything I've read about heroin. Ibogaine reset my receptors in one session. I wish I'd known about it two years earlier.”

Patient Profile

Age Range
Early 30s
Condition
Kratom dependence escalating to 7-hydroxymitragynine (7-OH) extract addiction
Duration
3 years total: 18 months plain leaf kratom, 18 months 7-OH concentrated extracts

Previous Treatment Attempts

  • ×Multiple cold-turkey quit attempts (severe withdrawal each time, lasted 2-3 days max)
  • ×Gradual self-taper (could not sustain, returned to full dose within weeks)
  • ×Ashwagandha, black seed oil, and supplement protocols (marginal symptom relief)
  • ×Consulted addiction specialists who dismissed kratom as 'not a real addiction'
  • ×Brief buprenorphine prescription (physician reluctant to prescribe for kratom, 2-week supply only)

Ibogaine TA Treatment Experience

The patient arrived at a specialized ibogaine clinic consuming the equivalent of 80+ grams of kratom daily through concentrated 7-OH extract products. Medical screening revealed elevated liver enzymes -- a common finding with heavy kratom use -- but cardiac function was normal. The clinical team noted that 7-OH extracts produce a withdrawal profile nearly identical to traditional opioids due to their potent mu-opioid receptor agonism. The ibogaine TA flood dose was administered after a 24-hour kratom cessation period. The patient reported that the experience was profoundly introspective, revealing that the kratom use had begun as self-medication for undiagnosed anxiety disorder. The TA formulation's multiple alkaloids provided comprehensive receptor modulation across the mu, kappa, and delta opioid systems -- all of which are affected by chronic kratom/7-OH use.

Outcome

Kratom/7-OH withdrawal symptoms eliminated within 8 hours of ibogaine administration. The patient reported no restless legs, no body aches, no anxiety -- symptoms that had previously made every quit attempt unbearable. Cravings for kratom were reduced by approximately 95%. Liver enzymes normalized within 6 weeks post-treatment.

Current Status

10 months kratom-free. Addressing underlying anxiety through therapy identified during the ibogaine experience. Reports dramatically improved sleep quality, restored libido, and resolution of the hair thinning that had developed during heavy kratom use. Advocates for greater awareness of kratom/7-OH addiction severity.

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

CASE 06Alcohol + Stimulant

Alcohol & Cocaine Dual Addiction

Twelve years of intertwined alcohol and cocaine dependence addressed through ibogaine's multi-receptor action

“Alcohol and cocaine were married in my brain. I couldn't use one without the other, and I couldn't stop either one. Rehab would address the drinking but ignore the coke, or vice versa. Ibogaine hit every receptor involved. For the first time in 12 years, both obsessions lifted at once.”

Patient Profile

Age Range
Mid 40s
Condition
Co-occurring alcohol use disorder (severe) and cocaine dependence
Duration
12 years of escalating use; alcohol daily, cocaine 4-5 times per week

Previous Treatment Attempts

  • ×Three 28-day inpatient rehab programs (relapsed within weeks of each discharge)
  • ×Antabuse (disulfiram) for alcohol (discontinued due to side effects)
  • ×Naltrexone for alcohol cravings (partial reduction, did not address cocaine)
  • ×Intensive outpatient programs (two separate attempts)
  • ×AA/NA (attended regularly for years, provided community but could not stop use)

Ibogaine TA Treatment Experience

Dual alcohol-cocaine addiction presents a unique pharmacological challenge because the two substances operate through different neurotransmitter systems: alcohol through GABA/glutamate, cocaine through dopamine reuptake. Most treatments target one system or the other. Ibogaine is uniquely positioned because it modulates multiple receptor systems simultaneously -- opioid, NMDA, serotonin, sigma, and nicotinic acetylcholine receptors. At the treatment clinic, the patient underwent medically supervised alcohol detoxification (5 days with benzodiazepine taper) before the ibogaine TA session. During the experience, the patient processed the social dynamics and emotional patterns that had intertwined the two substances into a single behavioral loop: drinking to socialize, cocaine to keep drinking, drinking to come down from cocaine.

Outcome

The ibogaine TA treatment disrupted the neurochemical reward pathways underlying both addictions simultaneously. Alcohol cravings were reduced substantially -- the patient described the change as 'the obsessive thinking just stopped.' Cocaine cravings were similarly diminished. The multi-alkaloid TA formulation's broad receptor coverage was particularly relevant here, as the combination of ibogaine, ibogamine, and tabernanthine provided modulation across the dopaminergic, serotonergic, and glutamatergic systems all implicated in this dual addiction pattern.

Current Status

11 months free from both alcohol and cocaine. Reports that social situations no longer trigger cravings -- a critical change since previous relapses were invariably triggered by social drinking environments. Rebuilt professional career in finance. Physical health dramatically improved: liver enzymes normalized, blood pressure returned to healthy range, 25 pounds lost. Attends integration therapy biweekly.

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

CASE 07Depression

Treatment-Resistant Depression

A decade of failed antidepressants and deteriorating quality of life reversed after safe SSRI tapering and ibogaine TA

“Ten years. Six antidepressants. TMS. Ketamine. Nothing lasted. Ketamine would lift the fog for two weeks, then it would come crashing back. After ibogaine TA, the fog didn't come back. It's been over a year and I still wake up wanting to be alive. I'd forgotten what that felt like.”

Patient Profile

Age Range
Late 30s
Condition
Major depressive disorder (treatment-resistant), classified after failure of 6+ medication trials
Duration
10 years of continuous depressive episodes despite active treatment

Previous Treatment Attempts

  • ×Six different SSRI/SNRI medications (sertraline, fluoxetine, escitalopram, venlafaxine, duloxetine, paroxetine)
  • ×Augmentation strategies (lithium, aripiprazole, bupropion -- partial or no response)
  • ×Transcranial magnetic stimulation (TMS -- 36 sessions, temporary mild improvement)
  • ×Ketamine infusion series (6 sessions -- significant but short-lived relief, 2-3 weeks per infusion)
  • ×Intensive psychotherapy (CBT, psychodynamic -- helpful for coping, did not resolve underlying depression)

Ibogaine TA Treatment Experience

This case required meticulous preparation. The patient was on paroxetine (40mg daily) -- an SSRI that must be completely cleared from the system before ibogaine administration due to dangerous serotonergic interactions. The medical team supervised a gradual 8-week paroxetine taper (reducing by 5mg every 10 days, with symptom monitoring and bridging support). After a 3-week washout period following complete cessation, the ibogaine TA flood dose was administered. The patient described the experience as 'a complete emotional recalibration.' Unlike ketamine, which had provided temporary numbing of depressive symptoms, the ibogaine experience facilitated deep processing of the formative experiences underlying the depression -- childhood emotional neglect that the patient had intellectually understood through therapy but never emotionally integrated. The TA formulation's serotonergic modulation, provided by the full spectrum of iboga alkaloids, appeared to produce a more comprehensive antidepressant effect than ibogaine HCL alone.

Outcome

Depression scores (PHQ-9) dropped from 22 (severe) to 6 (mild) within one week of treatment and remained stable. The patient described the change not as 'feeling happy' but as 'the weight being lifted -- colors were brighter, food tasted better, I wanted to be alive.' Noribogaine's sustained antidepressant action continued for months post-treatment, providing a neuroplasticity window during which the patient was able to consolidate therapeutic gains through integration work.

Current Status

13 months medication-free with sustained depression remission. PHQ-9 scores consistently in the 2-5 range (minimal to mild). Returned to creative work (painting, writing) abandoned during the decade of depression. Reports that ibogaine TA accomplished what six medications, TMS, and ketamine could not: a foundational shift in baseline mood rather than temporary symptom suppression. Plans a booster session at the 18-month mark as a preventive measure.

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

CASE 08Neurological

Parkinson's Disease Symptom Improvement

Early-onset Parkinson's patient experiences significant motor function recovery through ibogaine-mediated GDNF upregulation

“My neurologist told me Parkinson's only goes in one direction. After ibogaine, my tremor dropped by almost half. I could write my name again. I could button my shirt. My wife saw me walk across the room without freezing and just started crying. We both know this isn't a cure, but it's giving me my life back in a way nothing else has.”

Patient Profile

Age Range
Late 50s
Condition
Early-onset Parkinson's disease (Hoehn & Yahr Stage 2, bilateral involvement without balance impairment)
Duration
Diagnosed 4 years prior; symptoms (unilateral tremor) first noticed approximately 6 years ago

Previous Treatment Attempts

  • ×Carbidopa-levodopa (Sinemet) -- primary management, increasing dose requirements over time
  • ×Pramipexole (dopamine agonist) -- discontinued due to impulse control side effects
  • ×Physical therapy and exercise programs (beneficial but did not slow progression)
  • ×CoQ10, vitamin D, and neuroprotective supplement regimen (no measurable effect on symptoms)
  • ×Deep brain stimulation evaluation (deferred -- patient sought alternatives before surgical intervention)

Ibogaine TA Treatment Experience

Parkinson's patients require enhanced cardiac monitoring due to autonomic dysfunction common in the disease. The treatment protocol included baseline echocardiogram in addition to standard ECG, with continuous telemetry throughout treatment. The patient's MAO-B inhibitor (rasagiline) was discontinued three weeks before treatment due to contraindication with ibogaine. Carbidopa-levodopa was continued at a reduced dose. The ibogaine TA flood dose was administered with particular attention to hemodynamic stability. The patient reported a qualitatively different experience from addiction patients -- less autobiographical processing and more 'sensory and somatic' -- describing awareness of movement and coordination patterns during the introspective phase. The scientific rationale centers on ibogaine's potent stimulation of Glial Cell Line-Derived Neurotrophic Factor (GDNF), which protects and may regenerate dopamine-producing neurons in the substantia nigra.

Outcome

Motor symptom improvement became apparent within 5 days post-treatment. Unified Parkinson's Disease Rating Scale (UPDRS) motor scores improved by approximately 40%. Specific improvements included: resting tremor reduced substantially (patient could write legibly again), rigidity decreased in both upper extremities, bradykinesia (slowness of movement) notably improved, and gait freezing episodes reduced from several times daily to approximately once per week. The patient's neurologist confirmed objective improvement on clinical examination and noted that carbidopa-levodopa efficacy appeared enhanced, suggesting improved dopamine system function. Benefits peaked at approximately 3-4 weeks post-treatment and gradually diminished over 4 months, consistent with the expected timeline of GDNF-mediated neuroprotection.

Current Status

Returned for a second ibogaine TA treatment at the 5-month mark, with similar beneficial results. Now on a protocol of treatments approximately every 4-6 months. UPDRS scores remain consistently better than pre-ibogaine baseline even at the trough between treatments. Has deferred deep brain stimulation surgery indefinitely. Neurologist is supportive and monitoring. The patient describes the treatment as 'buying time against this disease -- every session gives me months of better function.'

Patient names and identifying details have been changed to protect privacy. Clinical outcomes are reported accurately.

These Results Are Possible Because of TA

Genuine Total Alkaloid extract from Tabernanthe iboga contains all 12+ alkaloids working in concert -- not just isolated ibogaine HCL from a substitute plant.

Most clinics worldwide use Ibogaine HCL semi-synthesized from Voacanga africana. The pharmacological difference between single-alkaloid HCL and full-spectrum TA is significant.

Understand the TA vs HCL Difference

Jump to a Case Study

CASE 01Fentanyl Addiction RecoveryOpioid AddictionCASE 02Oxycodone to FreedomPrescription OpioidsCASE 03Veteran PTSD & Opioid Dual DiagnosisPTSD + AddictionCASE 04Methadone LiberationMethadone DependenceCASE 05Kratom & 7-OH AddictionKratom / 7-OHCASE 06Alcohol & Cocaine Dual AddictionAlcohol + StimulantCASE 07Treatment-Resistant DepressionDepressionCASE 08Parkinson's Disease Symptom ImprovementNeurological

Evidence-Based Treatment Approach

What Leading Clinics Offer

The case studies on this page were treated at specialized ibogaine clinics in Cozumel, Mexico, using genuine Total Alkaloid (TA) extract from Tabernanthe iboga. This full-spectrum formulation provides the complete 12+ alkaloid profile the iboga plant evolved to produce, rather than a single isolated compound.Browse verified clinics →

The synergistic interaction of ibogaine, ibogamine, tabernanthine, voacangine, ibogaline, and the remaining alkaloids produces a fundamentally different therapeutic experience and outcome profile than isolated ibogaine HCL. This distinction is pharmacological, not marketing.

Medical Standards

  • +Comprehensive cardiac screening (12-lead ECG, echocardiogram when indicated) for every patient
  • +24/7 medical monitoring with continuous ECG telemetry during treatment
  • +Full blood panels, liver function, electrolyte assessment
  • +Specialized protocols for fentanyl, methadone, and complex cases
  • +Safe SSRI/SNRI tapering supervision for depression patients
  • +Enhanced cardiac protocols for Parkinson's and older patients
  • +Integration therapy and aftercare coordination included
Browse Ibogaine Treatment Clinics

Ready to Explore Treatment Options?

Every case study on this page began with someone who had exhausted every other option. If you are considering ibogaine treatment, start by assessing your eligibility and understanding the process.

Take the Pre-Screening AssessmentBrowse Treatment Clinics

Medical Disclaimer & Case Study Methodology

These case studies represent documented individual patient experiences at specialized ibogaine clinics and should not be interpreted as guarantees of specific outcomes. Ibogaine treatment results vary based on individual factors including substance use history, duration and severity of dependence, overall physical health, psychological readiness, adherence to aftercare protocols, and co-occurring conditions.

All patients underwent comprehensive medical screening including cardiac evaluation (12-lead ECG minimum), complete blood panels (liver function, kidney function, electrolytes), drug screening, medication interaction review, and psychological assessment before being cleared for treatment. Patients with contraindications including cardiac arrhythmias, prolonged QT interval, severe hepatic or renal impairment, active psychosis, or pregnancy were excluded from treatment.

Patient names, specific ages, locations, and other identifying details have been changed to protect privacy. Clinical details including conditions, treatment protocols, and outcomes are reported accurately based on medical records and patient follow-up.

Ibogaine is not approved by the FDA and is classified as a Schedule I substance in the United States. Treatment is conducted legally in Mexico under medical supervision. This information is provided for educational purposes and does not constitute medical advice. Always consult qualified healthcare professionals before pursuing any treatment.

Related Resources

What Is Ibogaine?

Comprehensive overview of ibogaine therapy

Safety Protocols

Medical screening and monitoring standards

Patient Testimonials

More patient stories and verified reviews

Treatment Process

Step-by-step guide to what to expect

Explore Related Topics

CommunityPatient TestimonialsResearchSuccess Rates & DataResearchScientific ResearchResearchClinical Trials 2026GuideConditions TreatedGuideAddiction TreatmentGuideAftercare & IntegrationCommunityFamily ResourcesClinicsFind a Clinic

These case studies document outcomes from specialized ibogaine clinics using Total Alkaloid (TA) extract. Find a verified treatment provider →